Novocure Reports Presentation Of Clinical Data From Phase 3 METIS Trial; Says Trial Met Its Primary Endpoint, Demonstrating Statistically Significant Improvement In Time To Intracranial Progression

Patients treated with TTFields therapy and BSC exhibited a median time to intracranial progression of 21.9 months compared to 11.3 months in patients treated with BSC alone (hazard ratio=0.67; P=0.016). Median TTFields therapy duration was 16 weeks and median usage was 67%. Baseline patient demographics and characteristics were well balanced between arms.